Company News

  • Reset
GOLDEN, Colo. — April 13, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced the launch of their new website aimed at expanding partner support with on-line tools for more rapid and efficient
View
GOLDEN, Colo. — February 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia, has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. Interim safety data of COVIGEN,
View
GOLDEN, Colo. — February 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that Chris Cappello, President and CEO of PharmaJet was featured in CEOCFO Magazine.
View
GOLDEN, Colo. — November 30, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, has been named “Asia’s Most Innovative Vaccine Delivery System” at the Asia-Pacific Vaccine Excellence Awards 2021 (AVEA 2021). The award was accepted by Paul LaBarre, MS, MBA, Vice President, Global Business Development, PharmaJet, Inc.
View
GOLDEN, Colo. — September 14, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis® and PharmaJet Stratis® Needle-free
View
GOLDEN, Colo. — June 30, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2. COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company
View
GOLDEN, Colo. — May 19, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in
View
GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding
View
GOLDEN, Colo. – Dec. 5, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that the first ever human clinical study of an mRNA rabies vaccine successfully showed immunogenicity when administered with their needle-free injection devices.
View
Menu